Navigation Links
Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research
Date:7/1/2009

an entirely novel cancer therapy, culminating in the production of an anti-HER2 monoclonal antibody that since 1998 has been used successfully to treat patients with metastatic breast cancer. This was the first targeted therapeutic agent developed on the basis of a newly discovered gene with an oncogenic function in human cancer.

In the early 1990s, Ullrich identified the signaling system involved in regulating tumor angiogenesis, the growth of blood vessels in tumors. He discovered that inhibiting a key player in the signaling system (called vascular endothelial growth factor receptor or VEGFR) suppresses the generation of blood vessels in tumors and slows down cancer cell growth. Years later, a small molecule inhibitor of the VEGFR2 kinase function was developed, from which a derivative was approved in 2006 for the treatment of kidney carcinoma and gastro-intestinal stromal tumors.

"It is an honor to receive an award of this stature and to be recognized among so many outstanding scientists," said Ullrich. "Dr. Paul is a legend whose work had a tremendous impact on combating some of the world's most serious diseases. Four of the more than 80 medicines he developed are on the World Health Organization's list of essential medicines."

"Johnson & Johnson is pleased the Selection Committee chose Dr. Ullrich as the recipient of the 2009 Dr. Paul Janssen Award, as we believe that his discoveries capture the spirit and legacy of Dr. Paul," said Paul Stoffels, M.D., global head, Research & Development, Pharmaceuticals, Johnson & Johnson. "Dr. Paul's passion for his work and dedication to creating life-saving therapies for the individuals most in need should continue to serve as an inspiration to the scientific community as we carry on with our quest to care for the world, one patient at a time."


'/>"/>

Contact: Seema Kumar Johnson & Johnson Pharmaceutical Services, L.L.C
skumar10@its.jnj.com
908-218-6460
Porter Novelli
Source:Eurekalert

Page: 1 2

Related biology news :

1. American Journal of Botany named a top 10 most influential journal of the century
2. New species of phallus-shaped mushroom named after California Academy of Sciences scientist
3. 3 prominent Cell Press journals named among the 100 most influential journals in past 100 years
4. Three prominent Cell Press journals named among the 100 most influential journals in past 100 years
5. Two Hutchinson Center researchers named HHMI Early Career Scientists
6. Peter Baumann named Howard Hughes Medical Institute Early Career Scientist
7. Whitehead member Peter Reddien named HHMI Early Career Scientist
8. Wildlife biologist named Roger Tory Peterson Medal recipient, speaker
9. Lockheed Martin Named Biometrics Company of the Year by Frost and Sullivan
10. Lockheed Martin Named Biometrics Company of the Year by Frost and Sullivan
11. UC San Diego senior named Churchill Scholar for extraordinary undergraduate research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... 2011 Reportlinker.com announces that a new market ... Biobanking: Technologies and Global Markets ... REPORT HIGHLIGHTS THIS REPORT ... biobanks by types: Population, Disease, and Private Sector ...
... YORK, July 14, 2011 ,   ... for consumer wellness applications,today announced that it has entered into ... US$5 Million equity,line facility. Under the terms of ... has the option to sell and Dutchess the,obligation to purchase ...
... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2011.   Revenue ... of 19% compared to $5.0 million in the same quarter last ... $267,000, or $0.01 per diluted share. These results compared to a ...
Cached Biology News:Biobanking: Technologies and Global Markets 2Biobanking: Technologies and Global Markets 3Biobanking: Technologies and Global Markets 4Biobanking: Technologies and Global Markets 5Biobanking: Technologies and Global Markets 6Biobanking: Technologies and Global Markets 7Biobanking: Technologies and Global Markets 8Biobanking: Technologies and Global Markets 9Biobanking: Technologies and Global Markets 10Biobanking: Technologies and Global Markets 11Biobanking: Technologies and Global Markets 12Biobanking: Technologies and Global Markets 13SPO Secures Equity Line Facility of US$5 Million 2SPO Secures Equity Line Facility of US$5 Million 3SPO Secures Equity Line Facility of US$5 Million 4Aware, Inc. Reports Second Quarter 2011 Financial Results 2Aware, Inc. Reports Second Quarter 2011 Financial Results 3Aware, Inc. Reports Second Quarter 2011 Financial Results 4Aware, Inc. Reports Second Quarter 2011 Financial Results 5
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) — ... online medical bill review and advocacy service, has signed ... FREE WellCard Savings discount health services marketplace. ... was more than they expected to pay. As part ... care costs, WellCard Savings is pleased to offer medical ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Australia, Jan. 30 Phosphagenics,Limited ("Phosphagenics") (ASX: POH, ... pre-clinical study demonstrating that the,combination of its APA- ... reduced serum lipids and inflammatory proteins,involved in the ... purpose of the study was to determine whether ...
... 30 Sagent Pharmaceuticals, Inc.,a privately-held specialty pharmaceutical ... that Ronald E. Pauli, chief financial,officer, will present ... Device Conference on Tuesday, February 5, 2008,at 11 ... 5-7, 2008 at the Grand,Hyatt Hotel in New ...
... Medical,Inc. (TASE: TOPMD) announces first commercial installation of ... Belgium,with the first procedures performed on January 16th., ... site to install the Cathamaran(TM),IVMRI System. This 6F ... to detect and quantify lipid present in coronary ...
Cached Biology Technology:Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination 2Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination 3Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination 4Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System 2Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System 3
... Detection of the yolk protein Vtg in plasma ... and sensitive biomarker for endocrine disrupting chemicals (EDCs) ... has become an accepted screening test for the ... (rainbow trout) EIA kit is a double-antibody immunometric ...
... whose sequence is from rat SCAMP 5. The sequence of ... - Q - P - Q - T - Q - ... - Y - T - Y - S - N(233). ... with the polyclonal antibody that reacts with this product and the ...
... which no antibody exists? Having difficulty generating antibodies ... variety of pharmaceutical, biotech and academic researchers and ... and expertise in antibody generation to work for ... development technology , High affinity and high specificity ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: